A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Summary
- Eligibility
- for people ages 40 years and up (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startedstudy ends around
- Principal Investigator
- by John A. Belperio, MD

Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- John A. Belperio, MD
Dr. John A. Belperio holds the Saul and Joyce Brandman Foundation Center for Lung Health Chair. He previously held the Guitiara Pierpoint Endowed Chair in Interstitial Pulmonary Fibrosis (4/3/2008 - 6/30/2025).
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Bristol-Myers Squibb
- Links
- BMS Clinical Trial Information BMS Clinical Trial Patient Recruiting Sign up for this study
- ID
- NCT06003426
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 1185 study participants
- Last Updated